Summary & Overview
HCPCS M1203: ACE inhibitor or ARB therapy not prescribed, reason not given
HCPCS Level II code M1203 denotes that ACE inhibitor or ARB therapy was not prescribed during the measurement period and no reason was provided. This documentation code is used in ambulatory care and outpatient medication management encounters to record omission of guideline-directed renin-angiotensin system therapy when a medication reconciliation or quality measure is assessed. Nationally, use of this code can affect quality reporting, gap-in-care identification, and case review workflows for conditions commonly treated with ACE inhibitors or ARBs.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how M1203 is applied across payer policies and quality programs and summarizes implications for claims documentation and reporting.
Readers will learn: the clinical context in which M1203 is used; the service type and typical site of service for code capture; how payers commonly treat documentation of omitted ACE/ARB therapy in administrative workflows; and which operational areas (quality measurement, medication reconciliation, and outpatient chronic disease management) are most affected. Data not available in the input will be identified as such in relevant sections.
Billing Code Overview
HCPCS Level II code M1203 indicates ACE inhibitor or ARB therapy not prescribed during the measurement period, reason not given. This code documents the absence of a prescribed angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) when a measurement or review of therapy is performed.
Service Type: Medication management / therapy omission documentation
Typical Site of Service: Outpatient clinic or ambulatory care setting, where medication reconciliation, chronic disease management, or quality-measure reporting occurs.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a history of hypertension and chronic kidney disease stage 3 presents for a routine primary care follow-up. The clinician documents that angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy was not prescribed during the measurement period and no reason for omission was recorded. During the visit the clinician reviews home blood pressures, current medications, and serum potassium and creatinine values. The workflow includes medication reconciliation, review of prior labs, assessment for contraindications (e.g., prior angioedema, hyperkalemia, pregnancy, bilateral renal artery stenosis), and documentation of clinical decision-making. The visit may result in initiation of alternative antihypertensive therapy, ordering labs to reassess renal function and electrolytes, scheduling follow-up, and counseling on lifestyle modifications. Typical sites of service include outpatient primary care clinic and ambulatory cardiology clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When additional work beyond usual is documented (e.g., complex medication reconciliation and additional counseling due to comorbidities). |
23 |